New Nature Genetics paper from Tekpli's group: Why do some breast cancers respond to hormone therapy while others do not?

Co-first authors flanked by co-senior authors
Co-first authors flanked by co-senior authors

In a study published on 4 November in Nature Genetics, Ilayda Altinönder and Villads Winton from Xavier Tekpli’s group, together with Jürgen Geisler, Senior Consultant in Medical Oncology at Ahus, and their co-authors identified biological differences between breast tumors that respond well to aromatase inhibitors and those that do not. 

Through longitudinal single-cell analyses of breast tumors, the authors found that tumors responding well to treatment were strongly associated with estrogen signaling, the pathway targeted by aromatase inhibitors.
Sensitivity to treatment was associated with a more active anti-tumor immune environment, including T cells and B cells that expanded and remained active during treatment.

Prize ceremony on Friday 13th November: Dr. Ragnar Mørk’s Prize for Excellent Cancer Research 2026

Kushtrim Kryeziu
Kushtrim Kryeziu

The prize of NOK 200.000 goes to Dr. Kushtrim Kryeziu, Department of Molecular Oncology, Institute for Cancer
Research, for his ground-breaking studies of how live tumour cells respond to specific drugs.

The prize ceremony will be on Friday 13th November in Seminar Rooms 1 and 2 in Institute for Cancer Research.

Program:
15:15 Introduction about Dr. Ragnar Mørk’s Prize by the legacy’s business manager, Carl Rieber-Mohn 
15:25 Introduction of the prize winner by the chair of the prize committee, Harald Stenmark
15:30 Prize winner’s lecture
16:00 Coffee and cake will be available for everyone after the lecture.
Prize committee: Harald Stenmark, Gunhild Mælandsmo, Olav Klingenberg, Rolf I. Skotheim

Link collection - current news: News stories involving OUS researchers

Oslo University Hospital partners in new EU-funded centre for theranostics in the Baltic region

Oslo University Hospital is the advanced partner in THERA-BALT, a new Horizon Europe project that will establish a Competence Centre for Theranostics and Radiopharmaceuticals in Lithuania. The centre will strengthen personalised cancer diagnosis and treatment in the Baltic region.

THERA-BALT started on 1 November 2026 and will run for five years. It is funded under the Horizon Europe Teaming for Excellence action, which helps research institutions become internationally competitive by working closely with leading European partners. The project is worth EUR 30 million in total: EUR 15 million from the European Union, with a further EUR 15 million planned from Lithuanian national funding.

The Jahre Lectures: prize distribution during seremony Nov 5th: Chloé B. Steen awarded the Anders Jahre Medical Prize for Young Researchers 2026

From The Jahre Lectures, Nov 5 2026
From The Jahre Lectures, Nov 5 2026

Chloé B. Steen, leader of the Cancer Biology in Silico project group at the Department of Medical Genetics at OUS and UiO, has been awarded the Anders Jahre Medical Prize for Young Researchers 2026.
Steen has developed advanced bioinformatic tools to characterise cells in tissues. Importantly, these tools have deepened our understanding of how cellular composition can influence cancer.
Open lectures by this year's winners of the Anders Jahre's Awards for Medical Research, Ole Kiehn, Heidi Haikala, and Chloé B. Steen, were held Nov. 5, 2026 10:00 AM–12:00 PM in Domus Bibliotheca, University of Oslo.

Fátima Carneiro receives the first Jan Vincents Johannessen Award

Portuguese pathologist Fátima Carneiro has been awarded the new Jan Vincents Johannessen Award “Fire in your heart” for outstanding research and promotion of onco-pathology. The award was presented at the Onco-Pathology Meeting in Oslo on 5 November.

The Jan Vincents Johannessen Award “Fire in your heart” is a new award recognizing outstanding onco-pathology research, the modernization of pathology, and leadership in the field. It is given to an exceptional pathologist in molecular cancer diagnostics who has demonstrated outstanding research, leadership and implementation that has reshaped onco-pathology. The award consists of a hand-made glass work of art and a personal prize of €20,000.

Changes to the Norwegian Health Research Act 

On 1 November 2026, the revised Norwegian Health Research Act entered into force. The amendments clarify that research institutions are responsible for ensuring that health research projects comply with applicable legal requirements.

Under the revised legislation, research-responsible managers and principal investigators must ensure that relevant legal compliance assessments are conducted before a project begins, throughout its lifecycle, and when it is completed.

These requirements emphasize the institutions’ responsibility for maintaining legal compliance and proper governance of health research projects.

Lynch Norge patient association officially registered: A new voice for people with Lynch syndrome

Many people in Norway with Lynch syndrome - a hereditary condition that carries a high risk of developing cancer -have long felt the need for an organization of their own to represent them. Lynch Norge has now been established to address this need. This is a direct result of PREDI-LYNCH, a research and innovation project aiming to determine whether blood tests, combined with risk models based on artificial intelligence, can help prevent cancer in individuals with Lynch syndrome. PREDI-LYNCH is funded through the EU’s Cancer Mission under the Horizon Europe programme, involving 16 different countries, including Norway.
Mev Dominguez-Valentin, leader of the Inherited and Familial Cancer research group at the Department of Tumor Biology at the Institute for Cancer Research, is the coordinator of PREDI-LYNCH.

New study identifies patients who benefit most from carboplatin treatment in aggressive breast cancer

Olav Engebråten
Olav Engebråten

Researchers at Oslo University Hospital and the University of Oslo have published results from the I-BCT-1 clinical trial (PI Prof. Olav Engebraaten) in Clinical Cancer Research, demonstrating a long-term benefit of adding carboplatin to neoadjuvant chemotherapy for patients with triple-negative breast cancer.

The study was initiated in 2014 to investigate whether adding carboplatin to standard chemotherapy could improve outcomes for patients with aggressive breast cancer. Among patients with triple-negative breast cancer, only 9% of those receiving carboplatin experienced disease recurrence, compared with 30% of patients treated with standard therapy alone. Such treatment approach recently became part of standard clinical care for this patient group. 

Page visits: 55668